Amneal Pharmaceuticals, Inc.

Informe acción NasdaqGS:AMRX

Capitalización de mercado: US$4.1b

Amneal Pharmaceuticals Crecimiento futuro

Future controles de criterios 4/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Amneal Pharmaceuticals de 48.9% y 6.9% por año respectivamente. Se prevé que el BPA crezca en un 47% al año. Se espera que la rentabilidad financiera sea de 52.6% en 3 años.

Información clave

48.9%

Tasa de crecimiento de los beneficios

46.99%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals12.8%
Tasa de crecimiento de los ingresos6.9%
Rentabilidad financiera futura52.59%
Cobertura de analistas

Low

Última actualización22 Apr 2026

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Amneal: A Robust Drug Portfolio Worth Watching, Driving Further Upside Potential

Apr 21

AMRX: 2026 EBITDA Plan And Inhalation Entry Will Drive Bullish Setup

Amneal Pharmaceuticals' analyst price target has shifted from $16.80 to about $17.17, with analysts pointing to recent target increases to $17 following solid Q4 results, 2026 EBITDA guidance strength, and a still intact long term growth thesis as key support for the updated view. Analyst Commentary Recent Street research around Amneal Pharmaceuticals has been concentrated on Q4 results, the new 2026 outlook, and how these feed into revised targets near $17.

AMRX: 2026 EBITDA Plan And Affordable Medicines Theme Will Drive Bullish Setup

Analysts have raised their price targets on Amneal Pharmaceuticals from $15 to $17, citing solid Q4 results, 2026 guidance that highlights stronger EBITDA expectations, and continued interest in the affordable medicines theme as key supports for the updated view. Analyst Commentary Analysts raising targets to $17 are largely focused on how Amneal executes against its 2026 plan and how that ties into the affordable medicines theme and EBITDA outlook.

AMRX: 2026 EBITDA Guidance Will Shape Bullish Setup Despite Recent Pullback

Narrative Update on Amneal Pharmaceuticals The analyst price target for Amneal Pharmaceuticals has been revised higher from $16.40 to $16.80. Analysts point to stronger FY26 EBITDA guidance and recent target increases to $17 at multiple firms as support for the updated view.

AMRX: 2026 EBITDA Outlook And Index Adds Will Shape Bullish Setup

Analysts have lifted their price target on Amneal Pharmaceuticals from $15.20 to $16.40, citing recent target hikes to $17 following solid Q4 results and 2026 guidance. The guidance highlights stronger EBITDA expectations despite more tempered revenue and margin assumptions, along with a higher future P/E of about 50x.

AMRX: Affordable Medicines Theme And Index Adds Will Shape Measured 2026 Setup

Analysts have nudged their price targets on Amneal Pharmaceuticals higher, with the updated fair value estimate moving from $14.40 to $15.20. This change is supported by recent Street research highlighting continued interest in affordable medicines and the company's role in that theme.

AMRX: Affordable Medicines Theme And Index Adds Will Shape Balanced 2026 Outlook

Analysts recently lifted their price target on Amneal Pharmaceuticals to $15 from $14, citing the company’s exposure to the affordable medicines theme as a key factor supporting their updated view. Analyst Commentary Recent commentary around Amneal Pharmaceuticals centers on its role in the affordable medicines theme and how that ties into expectations for execution and valuation heading into 2026.

AMRX: Affordable Medicines Theme And Q3 Execution Will Guide Fairly Balanced Outlook

Narrative Update Analysts have lifted their implied price target on Amneal Pharmaceuticals to about $14.40 from $14, reflecting higher Street targets of up to $15 and supportive views on both the affordable medicines theme and the company’s recent Q3 results versus expectations. Analyst Commentary Recent research updates focus on Amneal Pharmaceuticals' role in affordable medicines and the implications of its latest quarterly results for valuation and execution.

AMRX: Complex Generics Pipeline And Recent EPS Beat Will Shape Outlook

Analysts have nudged their fair value estimate for Amneal Pharmaceuticals higher to US$14.00 from US$13.80, reflecting updated price targets and recent quarterly results that came in ahead of prior Street EPS and revenue estimates. Analyst Commentary Bullish Takeaways Bullish analysts highlight that Q3 adjusted diluted EPS of US$0.17 came in ahead of prior Street expectations of US$0.14, which they see as a sign of solid execution against current earnings targets.

AMRX: Complex Generics Approvals Will Support Future Earnings Upside

Analysts have modestly raised their price target on Amneal Pharmaceuticals to approximately $13.80 from about $13.50, reflecting better than expected earnings and revenue performance in the latest quarter. Analyst Commentary Bullish Takeaways Bullish analysts highlight the earnings beat, with adjusted diluted EPS exceeding Street expectations, as evidence that management is executing effectively on cost control and product mix.

Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Nov 30
Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Price Is Right But Growth Is Lacking After Shares Rocket 25%

AMRX: Continued Execution and Pipeline Milestones Will Support Balanced Outlook

Analysts have raised their price target for Amneal Pharmaceuticals from $11 to $13, citing the company's stronger than expected third-quarter results and improved earnings outlook. Analyst Commentary Following the recent quarterly results, analysts have weighed in on Amneal Pharmaceuticals with a focus on both the company's strengths and areas for caution as they consider the revised price target.

AMRX: Sustained Outperformance Will Drive Future Earnings Confidence

Analysts have increased their price target for Amneal Pharmaceuticals from $11 to $13. They cite the company’s better-than-expected third-quarter earnings and revenue performance as the reason for this adjustment.

Amneal Pharmaceuticals' (NASDAQ:AMRX) Earnings May Just Be The Starting Point

Nov 14
Amneal Pharmaceuticals' (NASDAQ:AMRX) Earnings May Just Be The Starting Point

AMRX: Recent FDA Approvals And Pipeline Launches Will Drive Upside Momentum

Amneal Pharmaceuticals’ analyst price target has risen from $12.67 to $13.50, as analysts cite stronger revenue growth and an improved earnings outlook following the company’s recent results. Analyst Commentary Recent analyst updates indicate a mix of optimism and caution following Amneal Pharmaceuticals’ latest quarterly performance and forward guidance.

Global Health Trends And Pipeline Launches Will Fuel Future Potential

Amneal Pharmaceuticals' consensus price target has been raised as analysts now assign a higher future P/E multiple, increasing their fair value estimate from $12.00 to $12.67. What's in the News Amneal received FDA approval for its sodium oxybate oral solution 500 mg/mL (generic for Xyrem) for narcolepsy, expanding beyond prior limited authorized generic distribution.

Results: Amneal Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Aug 08
Results: Amneal Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Why Investors Shouldn't Be Surprised By Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Low P/S

Jul 24
Why Investors Shouldn't Be Surprised By Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Low P/S
User avatar

CREXONT And Metsera Partnerships Will Capitalize On Growing GLP-1 Market

The strategic collaboration in GLP-1 therapies and biosimilars expands market reach, poised to drive significant future revenue growth.

Amneal Pharmaceuticals: Shares Still Feel Significantly Undervalued

Mar 19

There's No Escaping Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Muted Revenues

Feb 17
There's No Escaping Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Muted Revenues

Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price

Nov 10
Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:AMRX - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
12/31/20283,5783475544354
12/31/20273,3301924943875
12/31/20263,10187N/A3725
12/31/20253,01972226340N/A
9/30/20252,9356237328N/A
6/30/20252,8533262351N/A
3/31/20252,830-13233307N/A
12/31/20242,794-117220295N/A
9/30/20242,680-184229313N/A
6/30/20242,598-175176252N/A
3/31/20242,495-169124201N/A
12/31/20232,394-84276346N/A
9/30/20232,38610137186N/A
6/30/20232,312-2114199N/A
3/31/20232,272-135-584N/A
12/31/20222,212-130-2565N/A
9/30/20222,139-13253152N/A
6/30/20222,122-13480140N/A
3/31/20222,0982161214N/A
12/31/20212,09411189242N/A
9/30/20212,06714219285N/A
6/30/20212,0589176247N/A
3/31/20211,987-17408478N/A
12/31/20201,99391313379N/A
9/30/20201,88062183222N/A
6/30/20201,739-194283317N/A
3/31/20201,679-19971159N/A
12/31/20191,626-362-962N/A
9/30/20191,727-339N/A312N/A
6/30/20191,825-67N/A234N/A
3/31/20191,834-69N/A115N/A
12/31/20181,663-21N/A250N/A
9/30/20181,459155N/A56N/A
6/30/20181,237149N/A67N/A
3/31/20181,083168N/A192N/A
12/31/20171,034168N/A234N/A
9/30/20171,03954N/A205N/A
12/31/20161,018207N/A115N/A
12/31/2015866169N/A105N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (48.9% al año) de AMRX es superior a la tasa de ahorro (3.4%).

Beneficios vs. Mercado: Se prevé que los beneficios (48.9% al año) de AMRX crezcan más rápidamente que el mercado US (15.8% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de AMRX crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (6.9% al año) de AMRX crezcan más despacio que el mercado de US (11% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 6.9% al año) de AMRX crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de AMRX sea muy elevada dentro de 3 años (52.6%).

Descubre empresas en crecimiento

7D

1Y

7D

1Y

7D

1Y

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/05/01 21:52
Precio de las acciones al final del día2026/05/01 00:00
Beneficios2025/12/31
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Amneal Pharmaceuticals, Inc. está cubierta por 20 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Glen SantangeloBarclays
Gary NachmanBMO Capital Markets Equity Research
David BuckB. Riley Securities, Inc.